PPIDT00224
Drug Information
| Name | Denosumab |
|---|---|
| Sequence | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB06643 |
| Type | biotech |
| Indication | Denosumab under the brand name Prolia is indicated as a treatment for osteoporosis in menopausal women or men and glucocorticoid-induced osteoporosis in men and women at high risk of fracture. It is also used to increase bone mass in men at high risk for fractures receiving androgen deprivation therapy for nonmetastatic prostate cancer or women at high risk for fractures receiving adjuvant aromatase inhibitor therapy for breast cancer.[L49796] Denosumab under the brand name Xgeva is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors and to treat giant cell tumors of bone in adults and skeletally mature adolescents and hypercalcemia of malignancy refractory to bisphosphonate therapy.[L49806] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
60 MG/ML
|
| Injection | Subcutaneous |
60 mg/1mL
|
| Injection, solution | Parenteral; Subcutaneous |
60 MG/ML
|
| Solution | Subcutaneous |
60 mg / mL
|
| Solution | Subcutaneous |
60.000 mg
|
| Injection, solution | Subcutaneous |
60 mg/ml
|
| Solution | Subcutaneous |
60 mg
|
| Solution | Subcutaneous |
60 mg/ml
|
| Solution | Subcutaneous |
6000000 mg
|
| Injection | Subcutaneous |
|
| Injection | Subcutaneous |
120 mg/1.7mL
|
| Injection | Subcutaneous |
70 MG/ML
|
| Injection, solution | Parenteral; Subcutaneous |
120 MG
|
| Solution | Subcutaneous |
120 mg / 1.7 mL
|
| Solution | Subcutaneous |
120.000 mg
|
| Injection, solution | Subcutaneous |
|
| Solution | Subcutaneous |
120 mg
|
| Injection, solution | Subcutaneous |
120 mg
|
| Solution | Subcutaneous |
12000000 mg
|
| Injection, solution | — |
120 mg/1.7ml
|
| Injection, solution | — |
60 mg/1ml
|